Consensus Avalo Therapeutics, Inc.

Stocks

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 23/10/2026 BST			5-day change	1st Jan Change
6.930 ^USD	-6.98%		-38.51%	-61.84%

10-23	Avalo Therapeutics Shares Fall After HC Wainwright Downgrade	MT
10-23	Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy	MT

Evolution of the Average Target: Avalo Therapeutics, Inc.

Evolution of the Target Price: Avalo Therapeutics, Inc.

Changes in Analyst Recommendations: Avalo Therapeutics, Inc.

f63f53d197ee55549.cH_9kXCTNEjOlNABwSEjZGfb_mGos88Ca5OyWU56s-E.AC6n2DnBUQn-waBxhFtGECu8kyrH1IRAEqrTPSs4_5AHGIT_FcYGHobiuw~69a20f393bf09ff7d114fc44e78c2e5c

Analysts' recommendations: Avalo Therapeutics, Inc.

10-23	Avalo Therapeutics Shares Fall After HC Wainwright Downgrade	MT
10-23	Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy	MT
10-23	HC Wainwright Downgrades Avalo Therapeutics to Neutral From Buy	MT
10-22	Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says	MT
10-22	Wedbush Adjusts Avalo Therapeutics Price Target to $22 From $34, Maintains Outperform Rating	MT
06-12	Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says	MT
06-12	BofA Initiates Avalo Therapeutics at Buy With $35 Price Target	MT
05-14	Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating	MT
05-06	Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating	MT
03-24	Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating	MT
02-02	Guggenheim Initiates Coverage on Avalo Therapeutics With Buy Rating, $50 Price Target	MT
12-18	Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target	MT
05/09/25	TD Cowen Initiates Avalo Therapeutics at Buy	MT
15/08/25	Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight	MT
25/03/25	Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target	MT
28/02/25	Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target	MT
21/02/25	Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target	MT
19/12/24	BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target	MT
24/10/24	HC Wainwright Initiates Avalo Therapeutics at Neutral	MT
16/04/24	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT
27/06/23	Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	MT
27/06/23	Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	MT
10/05/23	RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	MT
08/02/23	Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AVALO THERAPEUTICS, INC.					+455.56%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+66.36%
	Weighted average by Cap.					+23.77%